Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NRXS Stock Forecast 2025-2026
$2.44
Current Price
$17.61M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NRXS Price Targets
+94.7%
To High Target of $4.75
+94.7%
To Median Target of $4.75
+94.7%
To Low Target of $4.75
NRXS Price Momentum
+36.3%
1 Week Change
+16.2%
1 Month Change
-24.9%
1 Year Change
+3.8%
Year-to-Date Change
-35.4%
From 52W High of $3.78
+83.5%
From 52W Low of $1.33
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Neuraxis (NRXS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NRXS and similar high-potential opportunities.
Latest NRXS Stock Price Targets & Analyst Predictions
Wall Street analysts covering NRXS have a bullish consensus with a median price target of $4.75 (ranging from $4.75 to $4.75). Currently trading at $2.44, the median forecast implies a 94.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NRXS Analyst Ratings
1
Buy
0
Hold
0
Sell
NRXS Price Target Range
Low
$4.75
Average
$4.75
High
$4.75
Current: $2.44
Latest NRXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NRXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Neuraxis Inc. (NRXS) Competitors
The following stocks are similar to Neuraxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neuraxis Inc. (NRXS) Financial Data
Neuraxis Inc. has a market capitalization of $17.61M with a P/E ratio of 0.0x. The company generates $2.69M in trailing twelve-month revenue with a 86.5% profit margin.
Revenue growth is +43.2% quarter-over-quarter, while maintaining an operating margin of -192.7% and return on equity of -2,480.5%.
Valuation Metrics
Market Cap
$17.61M
Enterprise Value
$14.39M
P/E Ratio
0.0x
PEG Ratio
-24.4x
Price/Sales
6.6x
Growth & Margins
Revenue Growth (YoY)
+43.2%
Gross Margin
+86.2%
Operating Margin
-192.7%
Net Margin
+86.5%
EPS Growth
+43.2%
Financial Health
Cash/Price Ratio
+21.0%
Current Ratio
1.8x
Debt/Equity
22.9x
ROE
-2,480.5%
ROA
-169.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Neuraxis Inc. (NRXS) Business Model
About Neuraxis Inc.
What They Do
Develops innovative medical solutions for neurological health.
Business Model
Neuraxis Inc. operates as a biotechnology company focused on creating breakthrough therapies for neurological disorders. The company generates revenue through the development and commercialization of its medical solutions, which are aimed at addressing the increasing prevalence of various neurological conditions.
Additional Information
The company utilizes advanced research and technology to enhance treatment efficacy and patient outcomes in the neurology sector. As the demand for effective neurological treatments rises, Neuraxis Inc. is positioned to influence market dynamics and contribute significantly to the healthcare and pharmaceutical industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Mr. Brian Carrico
Country
United States
IPO Year
2023
Website
neuraxis.comNeuraxis Inc. (NRXS) Latest News & Analysis
Latest News
Quick Summary
NRXS reported strong revenue growth, expanded insurance coverage, and received new FDA clearances in Q4 2024.
Why It Matters
NRXS's strong revenue growth and expanded insurance coverage indicate increasing market acceptance, while FDA clearances can drive future sales, enhancing investor confidence and potential returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
NeurAxis, Inc. (NYSE: NRXS) will hold its Q4 2024 earnings conference call on March 20, 2025, at 9:00 AM ET. Key participants include CEO Brian Carrico and CFO Tim Henrichs.
Why It Matters
NeurAxis' Q4 earnings call will provide insights into its financial performance, potential growth, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
1 month ago
Quick Summary
NeurAxis, Inc. (NYSE: NRXS) reported its fourth quarter and fiscal year 2024 results, ending December 31, 2024, focusing on neuromodulation therapies for chronic conditions.
Why It Matters
NeurAxis's Q4 and FY 2024 results reveal the company's financial health and growth potential in the neuromodulation market, impacting stock performance and future investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NeurAxis, Inc. (NYSE American: NRXS) will release its Q4 and FY 2024 financial results on March 20, 2025, before market open, followed by a conference call at 9:00 am ET.
Why It Matters
NeurAxis's upcoming financial results and conference call can impact stock performance, indicating the company's health and future prospects in the neuromodulation market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NeurAxis, Inc. announced that Molina Healthcare will provide medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, enhancing its market reach.
Why It Matters
NeurAxis securing coverage for PENFS with Molina Healthcare expands its market access, potentially increasing revenues and enhancing growth prospects, which is favorable for investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NeurAxis, Inc. (NYSE American: NRXS) announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) with a major insurer covering 5.1 million members in 13 states.
Why It Matters
NeurAxis securing medical policy coverage for PENFS enhances its market potential, likely boosting revenue and stock performance, and indicating growing acceptance of its therapies in the healthcare industry.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NRXS Stock
What is Neuraxis Inc.'s (NRXS) stock forecast for 2025?
Based on our analysis of 0 Wall Street analysts, Neuraxis Inc. (NRXS) has a median price target of $4.75. The highest price target is $4.75 and the lowest is $4.75.
Is NRXS stock a good investment in 2025?
According to current analyst ratings, NRXS has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NRXS stock?
Wall Street analysts predict NRXS stock could reach $4.75 in the next 12 months. This represents a 94.7% increase from the current price of $2.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neuraxis Inc.'s business model?
Neuraxis Inc. operates as a biotechnology company focused on creating breakthrough therapies for neurological disorders. The company generates revenue through the development and commercialization of its medical solutions, which are aimed at addressing the increasing prevalence of various neurological conditions.
What is the highest forecasted price for NRXS Neuraxis Inc.?
The highest price target for NRXS is $4.75 from at , which represents a 94.7% increase from the current price of $2.44.
What is the lowest forecasted price for NRXS Neuraxis Inc.?
The lowest price target for NRXS is $4.75 from at , which represents a 94.7% increase from the current price of $2.44.
What is the overall NRXS consensus from analysts for Neuraxis Inc.?
The overall analyst consensus for NRXS is bullish. Out of 0 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.75.
How accurate are NRXS stock price projections?
Stock price projections, including those for Neuraxis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 9:17 PM UTC